27 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Long COVID (PASC) records define a time since infection and a symptom cluster. Some studies require documented SARS-CoV-2; others allow suspected infection. Treatments range from rehab to investigational drugs. Evidence is still evolving — the NCT page states what is being tested, not what is proven. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (17) · Phase 2 (6) · Phase 3 (2) · Phase 2 / Phase 3 (1) · Phase 1 (1)
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data.
NCT04362150 · Official ClinicalTrials.gov record · University of California, San Francisco
We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
NCT05764538 · Official ClinicalTrials.gov record · Chang Gung Memorial Hospital
This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.
NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.
NCT05851859 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de la Réunion
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.
NCT06366724 · Official ClinicalTrials.gov record · Brigham and Women's Hospital
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends.
NCT06577467 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)
The overarching goal of this study is to determine if baricitinib, as compared to dummy treatment (placebo), will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
NCT06631287 · Official ClinicalTrials.gov record · Wes Ely
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.
NCT06721949 · Official ClinicalTrials.gov record · University of Alberta
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain.
NCT06920628 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PASC.
NCT06928116 · Official ClinicalTrials.gov record · University of Nebraska
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months.
NCT06928272 · Official ClinicalTrials.gov record · Douglas D. Fraser
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects.
NCT06928506 · Official ClinicalTrials.gov record · University Health Network, Toronto
We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions.
NCT06933173 · Official ClinicalTrials.gov record · University of Alberta
This compared with a dummy treatment, randomly assigned, blinded, two-arm phase II study will test the safety and potential how well it works of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
NCT07021794 · Official ClinicalTrials.gov record · Nancy Klimas
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
NCT07123727 · Official ClinicalTrials.gov record · ImmunityBio, Inc.
This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance.
NCT07140094 · Official ClinicalTrials.gov record · Columbia University
The LIH DDP research team focuses its research topics on vocal biomarkers and Long COVID, among others. Voice is indeed a promising tool to monitor health, as it contains many information on our health and is easy to collect.
NCT07156994 · Official ClinicalTrials.gov record · Luxembourg Institute of Health
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.
NCT07316127 · Official ClinicalTrials.gov record · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition. The main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group.
NCT07530757 · Official ClinicalTrials.gov record · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a dummy treatment (placebo) (this does not contain the medications).
NCT07597902 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai
Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 (PASC).
NCT07661862 · Official ClinicalTrials.gov record · University of Tasmania
This proof-of-concept study aims to measure the feasibility, acceptability, and potential benefits of a novel multimodal approach: the micro-choice-based intervention.
NCT07726082 · Official ClinicalTrials.gov record · University Hospital, Basel, Switzerland
This study wants to better understand the biological changes associated with Long COVID and to identify laboratory tests (biomarkers) that may help diagnose the condition and measure how it changes over time. Researchers will enroll people with Long COVID as well as people who have fully recovered after COVID-19 infection.
NCT07770022 · Official ClinicalTrials.gov record · University of California, San Francisco
This study will examine how common Long COVID is and how symptoms may persist over time in people who have previously had COVID-19. Researchers will collect information about participants' health and symptoms through questionnaires and may collect saliva and other non-invasive oral samples.
NCT07781501 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill
This study investigates objective methods to measure and monitor fatigue in patients with post-COVID-19 condition (long COVID) and multiple sclerosis (MS), and includes a group of healthy volunteers for comparison. Fatigue is a common and debilitating symptom of both conditions, but current assessment methods rely mainly on questionnaires, which can be limited by subjectivity and recall bias.
NCT07783074 · Official ClinicalTrials.gov record · Liliana Barrios
In patients with post-COVID syndrome, changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more quickly when taking nicotinamide (vitamin B3).
NCT07798570 · Official ClinicalTrials.gov record · University Hospital Schleswig-Holstein
Chronic fatiguing illnesses such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia, and Long COVID are becoming a major global health challenge. They cause severe personal and social strain and have no proven, widely effective treatments.
NCT07874217 · Official ClinicalTrials.gov record · Oxford Brookes University
This hub lists 27 recruiting Long COVID studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “long COVID” at https://clinicaltrials.gov/search?cond=long%20COVID.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Zurich, Canton of Zurich; San Francisco, California; Edmonton, Alberta; Sherbrooke, Quebec; Boston, Massachusetts. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.